港股異動丨藥師幫高開近5%,2023年經調淨利首次全面轉正破1.3億元
藥師幫(9885.HK)高開4.97%報10.98港元,為連續第5日上升,且股價創去年12月18日以來新高,最新市值70.33億港元。消息面上,公司昨晚公佈2023年度業績公吿顯示,2023年全年,藥師幫總GMV達469.1億元,同比增長24%;營業收入169.7億元,同比增長18.9%;毛利額17.4億元,同比增長21.3%;年度經調整淨利潤全面轉正達1.3億元,同比22年的-1.25億元,實現歷史上首次年度規模性經營利潤;經營性現金流入超4.5億元,盈利能力持續穩步提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.